接受糖皮质激素治疗的绝经后妇女的维生素D水平及对双膦酸盐的反应 - Suppr

Suppr

超能文献

Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy.

作者信息

Ortego-Jurado M, Ríos-Fernández R, Callejas-Rubio J L, Gonzalez-Gay M A, Ortego-Centeno N

机构信息

Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario San Cecilio, Granada, Spain.

出版信息

Osteoporos Int. 2014 Aug;25(8):2157-8. doi: 10.1007/s00198-014-2713-6. Epub 2014 May 7.

DOI:10.1007/s00198-014-2713-6

PMID:24803328

Abstract

摘要

相似文献

Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy.

Osteoporos Int. 2014 Aug;25(8):2157-8. doi: 10.1007/s00198-014-2713-6. Epub 2014 May 7.

Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia.

Endocr Pract. 2011 Nov-Dec;17(6):873-9. doi: 10.4158/EP10339.OR.

Treating Low Vitamin D Levels Is Ineffective in Postmenopausal Women.

Am Fam Physician. 2016 Feb 15;93(4):315.

Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.

Calcif Tissue Int. 2011 Jun;88(6):485-94. doi: 10.1007/s00223-011-9482-4. Epub 2011 Apr 11.

[Vitamin D deficiency in postmenopausal women receiving osteoporosis therapy].

Lijec Vjesn. 2007 Aug-Sep;129(8-9):304.

Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation.

J Clin Endocrinol Metab. 2003 Nov;88(11):5175-9. doi: 10.1210/jc.2002-021968.

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.

Maturitas. 2010 Jul;66(3):291-7. doi: 10.1016/j.maturitas.2010.03.012. Epub 2010 Apr 15.

Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.

Eur J Cancer. 2018 Sep;101:87-94. doi: 10.1016/j.ejca.2018.06.028. Epub 2018 Jul 20.

Osteodensitometry in healthy postmenopausal women.

Prescrire Int. 2008 Apr;17(94):68-72.

The effect of cholecystectomy on 25-hydroxyvitamin D levels and bone mineral density in postmenopausal women.

Arch Osteoporos. 2018 May 22;13(1):61. doi: 10.1007/s11657-018-0458-0.

引用本文的文献

Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study.

J Osteoporos. 2015;2015:729451. doi: 10.1155/2015/729451. Epub 2015 Jun 1.

Vitamin D and bisphosphonate response.

Osteoporos Int. 2014 Aug;25(8):2155. doi: 10.1007/s00198-014-2711-8. Epub 2014 May 7.

本文引用的文献

25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis.

Bone. 2012 Jul;51(1):54-8. doi: 10.1016/j.bone.2012.03.026. Epub 2012 Apr 1.

The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.

Osteoporos Int. 2012 Oct;23(10):2479-87. doi: 10.1007/s00198-011-1868-7. Epub 2012 Jan 12.

Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies.

J Clin Endocrinol Metab. 2012 Mar;97(3):738-44. doi: 10.1210/jc.2011-2757. Epub 2011 Dec 21.

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6.

Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.

Calcif Tissue Int. 2009 Nov;85(5):398-404. doi: 10.1007/s00223-009-9295-x. Epub 2009 Oct 1.

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207. Epub 2009 Jun 1.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6.

The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.

BMC Musculoskelet Disord. 2007 Jan 10;8:3. doi: 10.1186/1471-2474-8-3.

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

J Bone Miner Res. 2000 Jun;15(6):1006-13. doi: 10.1359/jbmr.2000.15.6.1006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验